^
Association details:
| Biomarker: | ALK-ROS1 fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) + bemcentinib (BGB324) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 5262: Identifying the role of AXL in fusion kinase inhibitor resistant non-small cell lung cancer
Published date:
05/15/2020
Excerpt:
In screening our unique panel of patient-derived lung adenocarcinoma cell lines harboring ALK, ROS1 or RET gene fusions...Combining the AXL inhibitor R428 with TKI treatment, such as crizotinib for ALK and ROS1 driven cell lines, was effective at inhibiting colony formation and wound healing in fusion kinase inhibitor resistant cell lines.
DOI:
10.1158/1538-7445.AM2020-5262
